Keywords:
Abdomen, Kidney, Oncology, CT, Treatment effects, Neoplasia
Authors:
A. D. Sotomayor1, B. Paño Brufau2, J. M. Gutiérrez1, B. Mellado2, O. Reig2, M. C. Sebastia2; 1Barcelona, Barcelona/ES, 2Barcelona/ES
DOI:
10.1594/ecr2013/C-1596
Purpose
Antiangiogenic therapy induces a decrease in tumor vasculature but is of limited efficacy in tumor shrinkage (more cytostatic than cytotoxic).
Clinical trials have demonstrated that RECIST may underestimate the benefit induced by these new therapies (1).
New radiological criteria based on changes in vascular supply rather than size and density have provided better results than RECIST in monitoring therapeutic response.
As the new therapeutic agents for the treatment of mRCC inhibit angiogenesis,
tumor perfusion imaging may therefore be more appropriate for the assessment of tumor response.
Tumor vasculature can be evaluated using MR,
CT and US.
Advantages of perfusion-CT include its availability and the direct relationship between the perfusion parameters and tumor vascularity.
The main drawback is the high dose of radiation that CT delivers (2).
The objective of this poster is to evaluate the patterns of response to antiangiogenic therapy,
including evaluation of size,
density and perfusion-CT and compare the results of perfusion-CT with the clinical progression.